Sep 30, 2020

Jaguar Health Q3 2020 Earnings Report

Reported consolidated financial results for the third quarter of 2020.

Key Takeaways

Jaguar Health reported third quarter Mytesi net sales of approximately $2.8 million and gross sales of approximately $6.3 million. The increase in sales coincided with enhancements to the Mytesi patient access program, NapoCares™.

Mytesi net sales were approximately $2.8 million in Q3 2020.

Mytesi gross sales were approximately $6.3 million in Q3 2020.

Enhancements to the Mytesi patient access program, NapoCares™, coincided with the increase in sales.

Animal-related sales were minimal in Q3 2020 due to intentionally minimal commercialization efforts.

Total Revenue
$2.77M
Previous year: $973K
+185.0%
EPS
-$47.3
Previous year: -$450
-89.5%
Gross Profit
$1.99M
Cash and Equivalents
$1.35M
Free Cash Flow
-$2.92M
Total Assets
$36.2M

Jaguar Health

Jaguar Health

Jaguar Health Revenue by Segment